Emerging Targeted Therapies in the Management of Metastatic/Recurrent Head and Neck Cancer: Exploring the EGFR Pathways and the Potential Role of Biomarkers

Hollywood, FL US
March 14, 2014

Target Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Evaluate data from recent clinical trials of EGFRs in head and neck cancer, including data on emerging agents
  • Review key principles of therapy selection covered by aspects of current available guidance for metastatic/recurrent head and neck cancer
  • Discuss the potential implications of biomarkers on treatment choices
Additional information
Supporters: 

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
03/14/2014
Course expires: 
05/14/2014
Event starts: 
03/14/2014 - 12:00pm
Event ends: 
03/14/2014 - 1:00pm
Cost:
$0.00
The Westin Diplomat
3555 South Ocean Drive
Hollywood, FL 33019
United States

Barbara Burtness, MD
Fox Chase Cancer Center

Robert I. Haddad, MD
Dana-Farber/Brigham and Women’s Cancer Center |
Massachusetts General Hospital Cancer Center

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Accreditation Period

Course opens: 
03/14/2014
Course expires: 
05/14/2014

Price

Cost:
$0.00
Please login or register to take this course.